APPLE News
Liver Cancer 2021;10:164 –166 (Source: Liver Cancer)
Source: Liver Cancer - April 13, 2021 Category: Cancer & Oncology Source Type: research

Avelumab in Combination with Axitinib as First-Line Treatment in Patients with Advanced Hepatocellular Carcinoma: Results from the Phase 1b VEGF Liver 100 Trial
Conclusion: Treatment with avelumab plus axitinib was associated with a manageable toxicity profile and showed antitumor activity in patients with aHCC.Liver Cancer (Source: Liver Cancer)
Source: Liver Cancer - April 7, 2021 Category: Cancer & Oncology Source Type: research

Real-World Data on Clinical Outcomes of Patients with Liver Cancer: A Prospective Validation of the National Cancer Centre Singapore Consensus Guidelines for the Management of Hepatocellular Carcinoma
Conclusion: The high overall compliance rate and satisfactory clinical outcomes of patients managed according to the NCCS guidelines confirm its validity. This validation using real-world data considers patient and treating clinician preferences, thus providing a realistic analysis of the usefulness of the NCCS guidelines when applied in the clinics.Liver Cancer (Source: Liver Cancer)
Source: Liver Cancer - April 7, 2021 Category: Cancer & Oncology Source Type: research

Downstaging and Resection of Initially Unresectable Hepatocellular Carcinoma with Tyrosine Kinase Inhibitor and Anti-PD-1 Antibody Combinations
Conclusions: Combination of TKI/anti-PD-1 antibodies is a feasible conversion therapy for patients with unresectable HCC to become resectable. This study represents the largest patient cohort on downstaging role of combinational systemic therapy on TKI and PD-1 antibody for HCC.Liver Cancer (Source: Liver Cancer)
Source: Liver Cancer - March 30, 2021 Category: Cancer & Oncology Source Type: research

Disease Burden, Risk Factors, and Recent Trends of Liver Cancer: A Global Country-Level Analysis
Conclusion: We observed an overall increasing trend of liver cancer, especially among male subjects, older individuals, and countries with a higher prevalence of HCV-related liver cancer. More efforts are needed in enhancing lifestyle modifications and accessibility of antiviral treatment for these populations. Future studies should investigate the reasons behind these epidemiological changes.Liver Cancer (Source: Liver Cancer)
Source: Liver Cancer - March 30, 2021 Category: Cancer & Oncology Source Type: research

Time-Varying mHAP-III Is the Most Accurate Predictor of Survival in Patients with Hepatocellular Carcinoma Undergoing Transarterial Chemoembolization
Conclusion: An innovative time-varying analysis revealed that mHAP-III was the most accurate model in predicting OS in patients with HCC undergoing TACE. Other clinical pre- and post-TACE variables were also found to be relevant for this prediction.Liver Cancer (Source: Liver Cancer)
Source: Liver Cancer - March 17, 2021 Category: Cancer & Oncology Source Type: research

MRI Features for Predicting Microvascular Invasion of Hepatocellular Carcinoma: A Systematic Review and Meta-Analysis
Conclusions: Seven MRI features including larger tumor size, rim arterial enhancement, arterial peritumoral enhancement, peritumoral hypointensity on HBP, nonsmooth margin, multifocality, and hypointensity on T1WI were significant predictors for MVI of HCC. These MRI features predictive of MVI can be useful in the management of HCC.Liver Cancer (Source: Liver Cancer)
Source: Liver Cancer - March 11, 2021 Category: Cancer & Oncology Source Type: research

Reply to the Letter “Comment on Regarding Manuscript ‘Treatment of Intermediate Stage Hepatocellular Carcinoma in Japan: Position of Curative Therapies’”
Liver Cancer (Source: Liver Cancer)
Source: Liver Cancer - March 11, 2021 Category: Cancer & Oncology Source Type: research

Clinical Outcomes with Multikinase Inhibitors after Progression on First-Line Atezolizumab plus Bevacizumab in Patients with Advanced Hepatocellular Carcinoma: A Multinational Multicenter Retrospective Study
Conclusion: Second-line treatment with MKIs, mostly sorafenib and lenvatinib, showed comparable efficacy and manageable toxicities in patients with advanced HCC after disease progression on atezolizumab-bevacizumab.Liver Cancer (Source: Liver Cancer)
Source: Liver Cancer - March 3, 2021 Category: Cancer & Oncology Source Type: research

What Can Be Done to Solve the Unmet Clinical Need of Hepatocellular Carcinoma Patients following Lenvatinib Failure?
Conclusion: When ECOG PS and hepatic reserve function permit, continuing LEN treatment beyond PD, especially in u-HCC patients showed HFSR during LEN treatment, might be a good therapeutic option, at least until a more effective drug as a postprogression treatment after LEN failure is developed.Liver Cancer (Source: Liver Cancer)
Source: Liver Cancer - February 25, 2021 Category: Cancer & Oncology Source Type: research

Hepatic Arterial Infusion Chemotherapy Combined with Radiation Therapy for Advanced Hepatocellular Carcinoma with Tumor Thrombosis of the Main Trunk or Bilobar of the Portal Vein
Conclusion: Combination therapies of HAIC and RT might be good therapy for advanced HCC with Vp4.Liver Cancer (Source: Liver Cancer)
Source: Liver Cancer - February 24, 2021 Category: Cancer & Oncology Source Type: research

APPLE News
Liver Cancer 2021;10:82 –84 (Source: Liver Cancer)
Source: Liver Cancer - February 16, 2021 Category: Cancer & Oncology Source Type: research

Comment on the Manuscript “Treatment of Intermediate-Stage Hepatocellular Carcinoma in Japan: Position of Curative Therapies”
Liver Cancer (Source: Liver Cancer)
Source: Liver Cancer - February 16, 2021 Category: Cancer & Oncology Source Type: research

Sequential Therapy for Hepatocellular Carcinoma after Failure of Atezolizumab plus Bevacizumab Combination Therapy
Liver Cancer (Source: Liver Cancer)
Source: Liver Cancer - February 15, 2021 Category: Cancer & Oncology Source Type: research

Evolutions in the Management of Hepatocellular Carcinoma over Last 4 Decades: An Analysis from the 100 Most Influential Articles in the Field
Conclusions: Based on bibliometric analysis of the literature over the last 40 years, a comprehensive analysis of the most historically significant HCC management articles highlighted the key contributions made to the evolution and advancement of this specialist field. The data should provide clinicians and researchers insight into future directions relative to the advancement of HCC management.Liver Cancer (Source: Liver Cancer)
Source: Liver Cancer - February 2, 2021 Category: Cancer & Oncology Source Type: research